紫杉醇腹腔灌注化疗在晚期卵巢癌患者治疗中的效果分析

Effect analysis of paclitaxel intraperitoneal chemotherapy in the treatment of patients with advanced ovarian cancer

目的探讨紫杉醇腹腔灌注化疗在晚期卵巢癌患者治疗中的应用价值。方法选取2013年1月~2015年12月间我院接诊的晚期卵巢癌患者中90例作为研究对象,并通过抽签的方式将其平均分为观察组和对照组各45例,其中单纯予以紫杉醇+顺铂静脉滴注化疗的45例患者为对照组,在紫杉醇+顺铂静脉滴注化疗的基础上辅以紫杉醇腹腔灌注化疗的45例患者为观察组,探讨两种不同治疗方案在疗效、化疗前后肿瘤标志物水平以及化疗副反应等方面的差异。结果观察组患者治疗后的近期总有效率(91.11%)明显高于对照组(55.56%),差异有统计学意义(P<0.05);观察组患者的化疗毒副反应发生率为40.00%,明显低于对照组的64.44%,差异有统计学意义(P<0.05);与对照组患者相比,观察组患者化疗后的CA125、TPA水平更低(P<0.05);与对照组相比,观察组患者的无进展生存期、中位生存期明显延长(P<0.05)。结论晚期卵巢癌患者在选择紫杉醇+顺铂静脉滴注化疗的基础上辅以紫杉醇腹腔灌注治疗,不仅有助于治疗效果的提高,还能降低化疗副反应,延长患者生存期,疗效确切,值得推广。

Objective To explore the application value of paclitaxel intraperitoneal chemotherapy in the treatment of patients with advanced ovarian cancer, in order to improve the therapeutic effect of patients with advanced ovarian cancer. Methods According to the relevant requirements of the random number table method, 90 cases of patients with advanced ovarian cancer who were diagnosed from January 2013 to December 2015 were selected as subjects, and they were equally divided into observation group(n=45) and control group(n=45) by lottery. The control group was received intravenous chemotherapy with paclitaxel +cisplatin alone. The observation group was received paclitaxel and cisplatin intravenous infusion chemotherapy supplemented by intraperitoneal paclitaxel chemotherapy. The differences in efficacy,tumor marker levels before and after chemotherapy, and side effects of chemotherapy between the two different treatment regimens were investigated. Results The recent total effective rate(91.11%) in the observation group was higher than that in the control group(55.56%) after treatment(P<0.05). The total incidence of toxic and side effects during chemotherapy in the observation group was(40.00%), lower than that of the control group(64.44%)(P<0.05). Compared with those of the control group, the levels of CA125 and TPA were lower in the observation group after chemotherapy(P<0.05). The progression-free survival and median survival were more significantly prolonged in the observation group than those in the control group(P<0.05). Conclusion The treatment of paclitaxel + cisplatin intravenous infusion chemotherapy supplemented by paclitaxel intraperitoneal infusion therapy not only contributes to the improvement of therapeutic effect, but also reduces the side effects of chemotherapy and prolonged the survival of patients. It is worth promoting.